Announcements A Joint Statement on Technical, legal, ethical and implementation concerns regarding Aarogya Setu and other apps introduced during COVID-19 in India by Jan Swasthya Abhiyan (JSA), Internet Freedom Foundation (IFF), Forum for Medical Ethics Society (FMES), and All India People’s Science Network (AIPSN)   |   Submission to the National Human Rights Commission (NHRC) on behalf of Hub5 (HEaL Institute, APU, Seher-CHSJ, and IAPH) – COPASAH on human rights issues confronted by ASHAS and ANMs during the Covid-19 pandemic | Aug 7, 2020   |   Letter to MMC by FMES, PUCL-MH, FAOW, and MFC urging to restore its order suspending licenses of two doctors accused of abetting the suicide of Dr Payal Tadvi

Ethics of a placebo-controlled trial in severe mania

Vikram Patel

DOI: 10.20529/IJME.2006.004


In October 2005, editors of the IJME learnt that the British Journal of Psychiatry had published a report of a placebo-controlled trial of an atypical anti-psychotic drug. The drug was tested on 290 people experiencing an episode of acute mania. The trial was conducted on in-patients of eight health facilities in India.

Full Text





There are currently no refbacks.

Article Views

PDF Downloads

Click here to support US